Company news
Chongqing Genrix Biopharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Announcement on Resolutions of the 2024 Annual General Meeting
June 18, 2025
Announcement on Initial Public Offering of Restricted Shares under Strategic Allotment for Circulation
June 12, 2025
Announcement on Voluntary Disclosure on the Acceptance of New Drug Application for GR2001 Injection
May 22, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
May 19, 2025
Notice on Convening the 2024 Annual General Meeting
April 25, 2025
Preliminary Earnings Estimate for 2024
February 27, 2025
Announcement on the Voluntary Disclosure Regarding the Initiation of Phase III Clinical Trial for GR1802 Injection in the Indication of Chronic Spontaneous Urticaria
February 13, 2025
Voluntary Disclosure Announcement on the Approval of Marketing Application for New Indications of Xeligekimab
January 20, 2025
Annual Earnings Preannouncement for 2024
January 17, 2025
Announcement on Voluntary Disclosure on the Acceptance of New Drug Application for Silevimig Injection
January 14, 2025
Announcement on Completing General Election of Board of Directors and Board of Supervisors, and Appointing Senior Management Members, Head of Internal Audit Department and Securities Affairs Representative
December 24, 2024
Announcement on Term Change and Election of the Board of Directors and the Board of Supervisors
December 6, 2024